Inspire Medical Systems, Inc. (NYSE:INSP) Given Consensus Rating of “Moderate Buy” by Brokerages

Shares of Inspire Medical Systems, Inc. (NYSE:INSP) have received a consensus rating of “Moderate Buy” from the nineteen brokerages that are presently covering the firm, Marketbeat Ratings reports. One research analyst has rated the stock with a sell rating, seven have given a hold rating and eleven have assigned a buy rating to the company. The average 1-year price target among brokers that have covered the stock in the last year is $139.00.

Several research firms have issued reports on INSP. Royal Bank Of Canada lifted their target price on Inspire Medical Systems from $125.00 to $175.00 and gave the company an “outperform” rating in a research note on Wednesday, December 17th. Morgan Stanley reaffirmed an “equal weight” rating and issued a $130.00 price objective (up previously from $105.00) on shares of Inspire Medical Systems in a research report on Tuesday, December 2nd. Wolfe Research upgraded shares of Inspire Medical Systems from a “peer perform” rating to an “outperform” rating and set a $180.00 price objective for the company in a research note on Tuesday, November 25th. Oppenheimer restated an “outperform” rating on shares of Inspire Medical Systems in a research note on Friday, December 19th. Finally, Jefferies Financial Group reaffirmed a “hold” rating and set a $85.00 price target (down from $160.00) on shares of Inspire Medical Systems in a research report on Friday, October 24th.

Inspire Medical Systems Stock Down 1.7%

Shares of NYSE:INSP opened at $93.80 on Tuesday. The company has a market capitalization of $2.73 billion, a price-to-earnings ratio of 63.81, a price-to-earnings-growth ratio of 10.94 and a beta of 0.69. Inspire Medical Systems has a 52 week low of $70.77 and a 52 week high of $216.01. The firm has a 50 day moving average of $101.62 and a 200 day moving average of $101.59.

Inspire Medical Systems (NYSE:INSP) last announced its quarterly earnings results on Monday, November 3rd. The company reported $0.38 earnings per share (EPS) for the quarter, beating analysts’ consensus estimates of ($0.15) by $0.53. The business had revenue of $224.50 million for the quarter, compared to the consensus estimate of $220.39 million. Inspire Medical Systems had a return on equity of 9.41% and a net margin of 5.05%.The business’s revenue was up 10.5% compared to the same quarter last year. During the same period last year, the business posted $0.60 EPS. On average, sell-side analysts expect that Inspire Medical Systems will post 2.16 EPS for the current year.

Insiders Place Their Bets

In related news, Director Shawn Mccormick sold 2,000 shares of the company’s stock in a transaction dated Friday, November 28th. The stock was sold at an average price of $127.48, for a total transaction of $254,960.00. Following the transaction, the director directly owned 26,046 shares of the company’s stock, valued at $3,320,344.08. This represents a 7.13% decrease in their position. The sale was disclosed in a filing with the SEC, which is available at this link. 2.30% of the stock is currently owned by company insiders.

Institutional Investors Weigh In On Inspire Medical Systems

A number of large investors have recently modified their holdings of INSP. Dragoneer Investment Group LLC increased its holdings in shares of Inspire Medical Systems by 81.4% during the second quarter. Dragoneer Investment Group LLC now owns 2,354,411 shares of the company’s stock valued at $305,532,000 after acquiring an additional 1,056,808 shares in the last quarter. Wasatch Advisors LP grew its position in Inspire Medical Systems by 7.2% during the 2nd quarter. Wasatch Advisors LP now owns 1,634,395 shares of the company’s stock worth $212,095,000 after purchasing an additional 110,288 shares during the last quarter. William Blair Investment Management LLC increased its stake in Inspire Medical Systems by 68.7% during the 3rd quarter. William Blair Investment Management LLC now owns 1,297,573 shares of the company’s stock valued at $96,280,000 after purchasing an additional 528,404 shares in the last quarter. UBS AM A Distinct Business Unit of UBS Asset Management Americas LLC raised its holdings in shares of Inspire Medical Systems by 214.5% in the first quarter. UBS AM A Distinct Business Unit of UBS Asset Management Americas LLC now owns 1,112,925 shares of the company’s stock worth $177,267,000 after buying an additional 759,090 shares during the last quarter. Finally, Deerfield Management Company L.P. raised its holdings in shares of Inspire Medical Systems by 648.4% in the third quarter. Deerfield Management Company L.P. now owns 1,047,694 shares of the company’s stock worth $77,739,000 after buying an additional 907,694 shares during the last quarter. Hedge funds and other institutional investors own 94.91% of the company’s stock.

More Inspire Medical Systems News

Here are the key news stories impacting Inspire Medical Systems this week:

• Positive Sentiment: Inspire will present at the 44th Annual J.P. Morgan Healthcare Conference on Jan. 12 — an opportunity for management to update investors on remediation, commercial outlook and to answer questions that could calm markets if new details are constructive. Inspire Medical Systems, Inc. to Present at the 44th Annual J.P. Morgan Healthcare Conference
• Neutral Sentiment: Multiple national law firms are issuing investor alerts and reminding holders of a Jan. 5, 2026 lead-plaintiff deadline — these notices increase procedural legal activity but mainly reflect the crowding of counsel rather than new substantive disclosures. Representative notices include firms such as Faruqi & Faruqi and Bleichmar Fonti & Auld. INVESTOR ALERT: Inspire Medical Systems, Inc. (INSP) Investors are Notified to Contact BFA Law about the Pending Securities Fraud Class Action by January 5 Deadline
• Negative Sentiment: Several class-action complaints allege that Inspire concealed Medicare billing software failures and an inventory glut of the Inspire V device — accusations that reportedly preceded a ~$42 stock drop and have triggered multiple securities-fraud suits. Litigation and potential regulatory scrutiny raise near-term risks: legal costs, management distraction, possible financial exposure, and continued share-price volatility. INSP 1-WEEK DEADLINE ALERT: $42.04 Stock Drop at Inspire Medical Systems (INSP) Triggers Securities Fraud Lawsuit Over Concealed Medicare Billing Software Failures & Inspire V Inventory Glut
• Negative Sentiment: Multiple additional firms (Levi & Korsinsky, Rosen, Schall, Bronstein Gewirtz, DJS, Rosen, etc.) have filed or publicized actions and solicitations — amplification of claims increases media attention and may prolong volatility until company disclosures or legal resolutions occur. Contact Levi & Korsinsky by January 5, 2026 Deadline to Join Class Action Against Inspire Medical Systems, Inc. (INSP)

Inspire Medical Systems Company Profile

Inspire Medical Systems, Inc is a medical technology company specializing in implantable neurostimulation devices for the treatment of obstructive sleep apnea (OSA). The company’s flagship offering, the Inspire® system, delivers targeted stimulation of the hypoglossal nerve to maintain airway patency during sleep, providing an alternative therapy for patients who are intolerant of or inadequately managed by continuous positive airway pressure (CPAP) devices.

The Inspire system comprises an implantable pulse generator, a sensing lead that monitors breathing patterns, and a stimulation lead that activates the hypoglossal nerve.